temozolomide has been researched along with mk 2206 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Collier, AB; Gresh, RC; Kamara, DF; Kolb, EA; Sampson, VB; Vetter, NS | 1 |
Baumert, BG; Brands, E; Dik, R; Fedrigo, CA; Narayan, RS; Peters, GJ; Slotman, BJ; Sminia, P; Stalpers, LJ; Westerman, BA | 1 |
2 other study(ies) available for temozolomide and mk 2206
Article | Year |
---|---|
Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways.
Topics: Acetylation; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; G1 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 3-Ring; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sarcoma, Ewing; Signal Transduction; STAT3 Transcription Factor; Temozolomide; Tumor Suppressor Protein p53; Vorinostat | 2015 |
The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Synergism; Glioblastoma; Heterocyclic Compounds, 3-Ring; Humans; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Spheroids, Cellular; Temozolomide | 2017 |